This study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-
Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …

Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …

Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Importance Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …